If you liked this article you might like

Look for Clovis Oncology to Resume Its Advance
Goldman Sachs Raises Clovis Oncology Price Target to $75
6 Stocks Trending Up With Major Volume
AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results